Novartis targets Xolair successor in buyout of startup Excellergy
Source: BioPharma Dive - Latest News
Worth up to $2 billion, the deal is centered around a drug that could lead to faster and more complete control of allergic conditions than Novartis and Roche’s popular medicine.